Jorge, S. E., Schulman, S., Freed, J. A., VanderLaan, P. A., Rangachari, D., Kobayashi, S. S., . . . Costa, D. B. (2015). Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation. Lung Cancer.

Jorge, Susan E., Sol Schulman, Jason A. Freed, Paul A. VanderLaan, Deepa Rangachari, Susumu S. Kobayashi, Mark S. Huberman, and Daniel B. Costa. "Responses to the Multitargeted MET/ALK/ROS1 Inhibitor Crizotinib and Co-occurring Mutations in Lung Adenocarcinomas With MET Amplification or MET Exon 14 Skipping Mutation." Lung Cancer 2015.

Jorge, Susan E., et al. "Responses to the Multitargeted MET/ALK/ROS1 Inhibitor Crizotinib and Co-occurring Mutations in Lung Adenocarcinomas With MET Amplification or MET Exon 14 Skipping Mutation." Lung Cancer 2015.